[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mycobacterium-tuberculosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mycobacterium-tuberculosis":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,64,91,120,145,177],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":63},"100535583","phase-3-shortened-regimen-for-drug-susceptible-tb-in-children-100535583",false,"NCT06253715","Shortened Regimen for Drug-susceptible TB in Children","SMILE-TB","Inclusion Criteria:\n\n* Parent or guardian is willing and able to provide written informed consent for potential participant's study participation; in addition, when applicable per Ethics Committee\u002FInstitutional Review Board (EC\u002FIRB) policies and procedures, potential participant is willing and able to provide assent for study participation.\n* At Entry, age of less than 10 years.\n* At Entry, weight 3 kilograms (kg) or greater.\n* At Entry, diagnosed with TB disease, defined as:\n\n  * Pulmonary (including pleural effusion) and\u002For lymph node (extra-thoracic and\u002For intra-thoracic) TB with or without bacteriologic confirmation;\n  * Clinician has decided to treat with standard first-line drug-susceptible TB regimen.\n* Known HIV status or HIV testing in progress based on meeting testing requirements.\n* Has normal, Grade 1 or 2 test results for all of the following done at or within 14 days of Entry (including the most recent):\n\n  * Alanine aminotransferase (ALT) less than or equal to 5 times the upper limit of normal;\n  * Total bilirubin less than or equal to 2.5 times the upper limit of normal;\n  * Potassium level of 3.0 milliequivalent\u002FL or greater;\n  * Hemoglobin level of 7.0 g\u002FdL or greater;\n  * Platelet count of 100,000\u002Fmm3 or greater;\n  * Estimated glomerular filtration rate (eGFR; bedside Schwartz formula) 60 mL\u002Fmin\u002F1.73m2 or higher.\n* For children living with HIV:\n\n  * On antiretroviral therapy (ART) at Entry: Must be on, or able to be switched to a dolutegravir-based regimen at or prior to Entry;\n  * Not on ART at Entry: Planned initiation of dolutegravir before or at study Week 4.\n* For participants who have reached menarche or who are engaging in sexual activity (self-reported): negative serum or urine pregnancy test within 7 days of Entry.\n* For participants who are engaging in sexual activity that could lead to pregnancy (self-reported): agrees to practice at least one non-hormonal method of contraception or abstain from heterosexual intercourse during study drug treatment and for 30 days after stopping study medications. Non-hormonal methods include:\n\n  * Male or female condoms\n  * Diaphragm or cervical cap (with spermicide, if available)\n  * Non-hormonal intrauterine device (IUD) or intrauterine system (IUS)\n* At Entry, intends to remain in the catchment area of the study site for the duration of study follow-up or willingness to be followed up beyond the catchment area if\u002Fwhen applicable, as determined by the site investigator based on participant\u002Fparent\u002Fguardian report.\n\nExclusion Criteria:\n\n* Presumed or documented extra-pulmonary TB involving the central nervous system and\u002For bones and\u002For joints, and\u002For miliary TB, and\u002For pericardial TB and\u002For TB of the gastrointestinal (GI) tract and\u002For renal TB.\n* Premature infant (born less than 37-weeks gestation) who is less than 3 months of age at Entry.\n* Any known contraindication to taking any study drug:\n\n  * Known allergy or intolerance to any of the study drugs or drugs in the same class as the study drugs;\n  * Any prohibited medications within three days prior to Entry or planned use within the following 6 months;\n  * Unable to take oral medications;\n  * Known history of prolonged QT syndrome not caused by electrolyte derangements.\n* Received more than 10 days of treatment directed against TB disease within 6 months preceding initiation of study drugs.\n* M. tuberculosis isolate known or suspected to be resistant to isoniazid, rifampin, pyrazinamide, ethambutol, and\u002For fluoroquinolones.\n* Known exposure to an infectious adult with drug-resistant TB, including resistance to isoniazid, rifampin, pyrazinamide, ethambutol, and\u002For fluoroquinolones.\n* Has any other documented or suspected clinically significant medical condition or any other condition that, in the opinion of the site investigator, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.\n* Previously enrolled in this study.\n\nLate Exclusions:\n\n* M. tuberculosis cultured or detected through World Health Organization (WHO) approved molecular assays (e.g., Cepheid Xpert MTB\u002FRIF, Xpert XDR, sequencing or Hain MTB-DR plus assays) from sputum, swallowed sputum, nasopharyngeal aspirates, stool, or lymph node aspirate obtained around the time of study entry is determined to be resistant to isoniazid and\u002For rifampin and\u002For pyrazinamide and\u002For ethambutol and\u002For fluoroquinolones.\n* Any child with a clinical TB diagnosis who is found to have a definitive alternative diagnosis for their presenting signs and symptoms whose TB treatment is discontinued prior to completion.","ALL","0 Days","9 Years",{"count":20,"type":21},860,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","While drug-susceptible tuberculosis (TB) disease in children currently requires four to six months of treatment, most children may be able to be cured with a shorter treatment of more powerful drugs. Shorter treatment may be easier for children to tolerate and finish as well as ease caregiver strain from managing treatment side effects and supporting children over many months. The primary objective of this study is to evaluate if a 2-month regimen (including isoniazid (H), rifapentine (P), pyrazinamide (Z) and moxifloxacin (M)) is as safe and effective as a 4- to 6-month regimen (isoniazid, rifampicin (R), pyrazinamide, ethambutol (E)) in curing drug-susceptible TB disease in children under 10 years old. The study is also evaluating the safety of the HPZM in children with and without HIV.",[27,28,29,30],"Tuberculosis","Tuberculosis, Pulmonary","Tuberculosis, Lymph Node","Mycobacterium Tuberculosis",[32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50],"tuberculosis","pediatric","stratified medicine","shortened regimen","rifapentine","moxifloxacin","dolutegravir","drug-susceptible","lymph node","pulmonary","infections","TB","mycobacterium infections","respiratory tract infections","lung diseases","antitubercular agents","respiratory tract diseases","child","paediatric","RECRUITING","2026-05-28",{"date":54,"type":55},"2026-06-01","ACTUAL",{"date":57,"type":55},"2025-01-15",{"date":59,"type":21},"2027-09-30",{"name":61,"class":62},"Johns Hopkins University","OTHER",9,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":72,"sex":16,"minAge":73,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":76,"phases":4,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":88,"locationsCount":90},"100581077","blood-tuberculosis-dna-levels-to-monitor-tuberculosis-treatment-100581077","NCT06845618","Blood Tuberculosis DNA Levels to Monitor Tuberculosis Treatment","Mycobacterium Tuberculosis Complex Cell-free DNA (Mtb-cfDNA) for the Pharmacometric Assessment of Anti-tuberculosis Treatment: a Proof-of-concept Study","Mtb-Dynamic","Inclusion Criteria:\n\nParticipants with a new diagnosis of tuberculosis\n\n* Aged ≥ 18 years old\n* Newly microbiologically confirmed (culture or nucleic acid amplification test) diagnosis of Mycobacterium tuberculosis (Mtb.) infection (of any site)\n* Has not yet commenced antituberculosis therapy\n* Able to understand study procedures and requirements and is able to give informed consent\n\nFor healthy volunteers:\n\n* Aged ≥ 18 years old\n* Healthy as judged by a responsible physician\n* Able to understand study procedures and requirements and is able to give informed consent\n\nExclusion Criteria:\n\nParticipants with a new diagnosis of tuberculosis\n\n* Exposure to antituberculosis treatment in the last 8 weeks (or Mycobacterium tuberculosis (Mtb.) active fluoroquinolone)\n* Known history of underlying malignancy\n* Pregnancy\n* Transfusion dependent anaemia\n\nFor healthy volunteers:\n\n* History of tuberculosis infection or latent tuberculosis infection\n* Household, or other close contact, of a person living with tuberculosis disease\n* Chest radiograph (CXR) changes suggestive of pulmonary tuberculosis\n* Presence of symptoms which would otherwise indicate screening for tuberculosis (cough \\> 2 weeks duration, fever, weight loss, night sweats)\n* Other major medical comorbidity\n* Pregnancy\n* Known malignancy",true,"18 Years",{"count":75,"type":21},140,"OBSERVATIONAL","Tuberculosis (TB) is a leading infectious cause of death worldwide. Current strategies for monitoring TB treatment response are culture dependent and insensitive. New methods of assessing treatment response in vivo could inform new drug development and other treatment strategies. Cell-free DNA (cfDNA) - small circulating fragments of DNA - is widely used in maternofetal medicine and oncology for diagnosis and assessment of treatment response. This study aims to investigate whether pathogen derived Mycobacterium tuberculosis-specific cfDNA (Mtb-cfDNA) can be used to monitor TB treatment response.\n\nThis feasibility study will take place at Mae RaMat TB Center in Thailand and includes two study groups:\n\n1. Assay Development and Validation\n2. Longitudinal Assessment of Mtb-cfDNA levels",[30,28,79],"Tuberculosis, Extra-Pulmonary",[81],"cfDNA","2026-04-07",{"date":84,"type":55},"2026-04-13",{"date":86,"type":55},"2025-07-21",{"date":59,"type":21},{"name":89,"class":62},"University of Oxford",1,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":73,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":22,"phases":101,"briefSummary":102,"conditions":103,"keywords":107,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":90},"100630311","phase-3-feasibility-of-the-application-of-a-new-six-month-treatment-for-multidrug-resistant-tuberculosis-mdr-tb-patients-in-france-fast-mdr-100630311","NCT07486024","Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France (FAST-MDR)","Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France - FAST-MDR","FAST-MDR","Inclusion criteria\n\n1. Is 18 years old or more\n2. Is affected by bacteriologically- or molecularly-confirmed tuberculosis, due to strains of M. tuberculosis resistant to rifampicin (with or without resistance to isoniazid) according to a rapid molecular test\n3. Is willing and able to give informed consent to be enrolled in the research project (signed or witnessed consent if the patient is illiterate)\n4. Patients seen in consultation or hospitalized in one of the centers involved for rifampicin-resistant TB, with screening results available and compatible within 14 days following consent signature;\n5. Is willing to use effective\\* contraception: women with childbearing potential\\*\\* must agree to use effective contraception, unless their partner has had a vasectomy, for the duration of study treatment and up to 6 months after the end of study treatment; men who have not had a vasectomy must agree to use effective contraception for the duration of study treatment and up to 3 months after the end of study treatment;\n\n   * The following contraception methods are considered effective, according to local regulation (CTFG recommendations, March 2024):\n\n     1. Combined hormonal contraception (oestrogen + progestin)\n     2. Progestin-only hormonal contraception\n     3. Intrauterine device (IUD)\n     4. Intrauterine hormone-releasing system (IUS)\n     5. Bilateral tubal occlusion\n     6. Vasectomised partner\n\n        * A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.\n6. Is affiliated to a social security system (as beneficiary) or has state medical aid (AME) or has an ongoing demand for AMEor has an ongoing demand for an emergency medical care (dispositif de soins d'urgence, as applicable for tuberculosis)\n\nExclusion criteria :\n\n1. Is unable to take oral drugs\n2. Has known allergies, hypersensitivity or intolerance or any other medical condition and contra indications to any drug of the regimen\n3. Unwilling to comply to study procedures, at the clinician appreciation\n4. Has proven or likely resistance to bedaquiline, clofazimine, linezolid, pretomanid or moxifloxacine, or has had exposure (for 30 days or more) in past five years to bedaquiline, clofazimine, delamanid, linezolid, or pretomanid\n5. Is taking or needs to take contraindicated medications in association with investigational medicinal products\n6. Has ≥500 msec QTcF interval on any ECG taken at screening or baseline visits, or has any cardiac risk factor for severe arrhythmia\n7. Has severe extrapulmonary TB, including meningo-encephalitis, brain abscess, osteo-arthritis, osteomyelitis\n8. Is concurrently participating in another trial of any medicinal product\n9. Is already on a MDR\u002FRR-TB treatment regimen since 4 weeks or more, and has no need to change the treatment regimen (i.e. adverse events, treatment failure)\n10. Has significant and uncorrectable lab abnormalities at baseline: haemoglobin ≤7.9 g\u002FdL, platelet count \\\u003C75 000\u002Fmm3; absolute neutrophil count \\\u003C1 000\u002F mm3; potassium \\\u003C3.0 mEq\u002FL; serum creatinine \\>3 x upper level of normality (ULN); alanine aminotransferase (ALT) ≥3 x ULN\n11. Has peripheral neuropathy of grade 3 or 4 (CTCAE scale)\n12. Has any other condition (social or medical) which, in the opinion of the site investigator, would make the study participant unsafe\n13. Is known to be pregnant or is unwilling or unable to stop breastfeeding an infant\n14. Individuals permanently legally incompetent adults, under judicial or administrative protection and vulnerable persons",{"count":100,"type":21},55,[24],"The FAST-MDR trial is an externally-controlled, multicentre trial with one prospective arm, evaluating the non-inferiority of the effectiveness of BPaLM in the interventional arm versus the effectiveness of the long, conventional regimen in a French historical cohort of MDR-TB patients (2006-2022). In light of recent WHO recommendations suggesting using BPaLM as a first choice for routine MDR-TB treatment and of the expected benefits of BPaLM over the standard treatment, there will be no internal comparator arm in the study.",[104,105,106,30],"MDR-TB","Tuberculosis Multi Drug Resistant Active","Antibiotic Resistance",[104,108,109],"BPaLM","Tuberculosis Multi Drug Resistant","NOT_YET_RECRUITING","2026-03-17",{"date":113,"type":55},"2026-03-20",{"date":115,"type":21},"2026-04",{"date":117,"type":21},"2032-02",{"name":119,"class":62},"Assistance Publique - Hôpitaux de Paris",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":16,"minAge":73,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":76,"phases":4,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":144},"100605083","evaluation-of-pathfast-lam-as-a-tuberculosis-treatment-monitoring-tool-in-kenya-100605083","NCT07157904","Evaluation of PATHFAST-LAM as a Tuberculosis Treatment Monitoring Tool in Kenya","Evaluating the PATHFAST TB LAM Ag Assay as a Treatment Monitoring Tool for Pulmonary Tuberculosis: A Prospective Longitudinal Study in Nairobi, Kenya","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Patients with a recent diagnosis of bacteriologically confirmed PTB who have not yet initiated TB treatment.\n* Patients who are willing and able to visit to the facility for follow-up sample collection and interviews.\n* Patients who are willing and able to provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n\\- Patients with a history of TB treatment within the past 6 months, including retreatment.",{"count":128,"type":21},300,"Tuberculosis (TB) can be treated; however, the standard 6-month treatment is long and challenging for many patients, and 10-20% still don't recover well by the end of treatment. Thus, it's important to regularly check if the treatment is working to help patients get better and prevent drug-resistant TB from developing. It can, however, be especially hard to check if TB treatment is working in places with limited resources. Traditional methods, such as testing sputum samples for microscopy and culture, have limitations. Lipoarabinomannan (LAM) is a substance that is found in the cell wall of the bacteria that cause TB, which can be used as an indicator for TB diagnosis and treatment monitoring. The PATHFAST TB LAM Ag test is a fully automatic machine that checks for LAM in sputum. It could offer a faster and more accurate way to see if TB treatment is working. This study aims to find out how helpful the PATHFAST-LAM test is in monitoring TB treatment progress among Kenyan TB patients.\n\nThe primary objective of this study is to assess whether changes in sputum LAM levels can help predict unfavorable results.\n\nIn this study, investigators will recruit adult patients diagnosed with pulmonary TB from multiple healthcare facilities in Nairobi, Kenya. Investigators will follow them during their TB treatment and collect sputum and urine samples at the beginning of treatment, then, every week for the first month, every two weeks for the next two months, and monthly for months 3-6. Investigators will use the PATHFAST-LAM test to measure LAM levels in sputum and urine. Since there are no previous studies that have evaluated the relationship between sputum LAM and treatment outcome, investigators will do an initial analysis with 30 participants, and based on that, investigators will determine the final number of participants needed for our study.\n\nIt is expected that sputum LAM decreases when the treatment is successful and remains positive (does not decrease) when treatment is unsuccessful, with patients experiencing unfavorable results. How LAM decreases during the earlier course of TB treatment may be useful in predicting patients' outcomes. The results of this study could provide a faster and effective way for monitoring TB treatment. This could contribute to improved patient outcomes and help reduce the global burden of TB.",[27,131,30],"Pulmonary Tuberculoses",[27,133,134],"Treatment Monitoring Tool","Lipoarabinomannan","2025-09-05",{"date":137,"type":55},"2025-09-12",{"date":139,"type":21},"2026-01",{"date":141,"type":21},"2027-07",{"name":143,"class":62},"Nagasaki University",2,{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":153,"enrollmentInfo":154,"targetDuration":156,"studyType":76,"phases":4,"briefSummary":157,"conditions":158,"keywords":159,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":176},"100289188","diagnosis-of-tuberculosis-in-swiss-children-100289188","NCT03044509","Diagnosis of Tuberculosis in Swiss Children","Evaluation and Validation of Novel Immunodiagnostic Tests for Childhood Tuberculosis Infection and Disease in Switzerland. The CITRUS (ChIldhood TubeRcUlosis in Switzerland) Study.","CITRUS","Inclusion Criteria:\n\n* all children \u002F adolescents \\\u003C 18 years of age undergoing evaluation for TB exposure, infection or disease.\n\nExclusion Criteria:\n\n* children \u002F adolescents with TB infection or disease who have already been started on anti-mycobacterial treatment, children who have been treated for TB previously.","17 Years",{"count":155,"type":21},190,"2 Months","1. The primary objective is to improve the sensitivity of novel immunodiagnostic tests for detection of TB disease in children.\n2. The secondary objective is to determine biomarkers that discriminate children with TB infection and disease.",[27,30],[160,161,162,163,164,165,166],"Immunodiagnostics tests","TB exposure","Latent TB","TB disease","Biomarkers","Metabolomics","NMR","2024-09-05",{"date":169,"type":55},"2024-09-19",{"date":171,"type":55},"2017-05-12",{"date":173,"type":21},"2028-12",{"name":175,"class":62},"University Children's Hospital Basel",8,{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":76,"phases":4,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":90},"100556950","characteristics-and-outcomes-of-tb-and-hiv-co-infections-100556950","NCT06531772","Characteristics and Outcomes of TB and HIV Co-infections","Inclusion Criteria:\n\n* Laboratory diagnosis of TB-HIV co-infection\n\nExclusion Criteria:\n\n* Patients refusing to participate in the study",{"count":184,"type":21},100,"People Living with HIV (PLHIV) are prone to several opportunistic infections depending on the degree of immunosuppression as well as infections prevalent in their geographic area\u002Fcountry. These include a wide variety of mycobacterial diseases, fungal infections, bacterial pneumonias, pneumocystis jirovecii pneumonia, cryptococcal infections, toxoplasmosis etc.\n\nTuberculosis remains the most common opportunistic infection in the developing countries like South Africa and India.\n\nHIV and tuberculosis (TB) are two of the most challenging infections faced by the humanity. HIV is the most important risk factor for progression of latent Mycobacterium tuberculosis (MTB) to active disease. The most common cause of death among PLHIV is tuberculosis. These two infections place immense burden on health care systems worldwide. During the last two decades, sustained research and public health initiatives on prevention and therapeutic advances have allayed morbidity and mortality due to HIV and TB to a large extent, however more needs to be done.\n\nGlobally, an estimated 10 million people fell ill with TB and an estimated 1.4 million people died of TB in 2018 (1.2 million among HIV negative and 251 000 among HIV positive people). There were around 37.9 million PLHIV worldwide in 2018.\n\nIn the pre-antiretroviral therapy (ART) era, nearly one-third of HIV\u002FAIDS (acquired immune deficiency syndrome) related deaths were due to TB. Wider availability of ART has reduced the mortality of HIV-associated TB significantly, but it still remains high compared to HIV-uninfected individuals. The mortality risk with HIV TB coinfection accounts for approximately 25% of global HIV\u002FAIDS deaths every year.\n\nThis study aims to investigate characteristics and outcomes of TB and HIV co-infections in Upper Egypt.",[187,30],"Human Immunodeficiency Virus","2024-07-29",{"date":190,"type":55},"2024-08-01",{"date":192,"type":55},"2023-09-01",{"date":194,"type":21},"2025-03-01",{"name":196,"class":62},"Assiut University"]